Get started
Author

Francesca Maria Gay

Observed names: F Gay, Francesca Gay, Francesca Marianatal Gay, Gay, Francesca
OpenAlex ID: A5043014171
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.
2013 · Mario Boccadoro, Federica Cavallo, et al. · Journal of Clinical Oncology · 19
Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
2017 · Francesca Maria Gay, Delia Rota Scalabrini, et al. · Journal of Clinical Oncology · 17
Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.
2018 · Martin Gramatzki, Andreas Guenther, et al. · Journal of Clinical Oncology · 9
Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).
2018 · Francesca Maria Gay, Robin Foà, et al. · Journal of Clinical Oncology · 3
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
2026 · Michela Cumerlato, Monica Maccagno, et al. · Haematologica · 2
Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor
2018 · Katja Weisel, Maria-Victoria Mateos, et al. · Blood · 1
Policy approach to optimize multiple myeloma treatment sequencing practices
2026 · Zsuzsa Réka Pozsár, Solène Clavreul, et al. · Expert Review of Hematology
B05: Results From a Meta-analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice of Treatment in Patients With Relapsed or Refractory Multiple Myeloma
2022 · F Gay, JG Berdeja, et al. · HemaSphere
Works count: 9
Citation count: 51
H-index: 3
I10-index: 2
Year
Topic
Type